SCHEMBL24252876

SCHEMBL24252876

COc1ccc(CNc2ccnc3ccc(Br)cc23)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.56
ADRA1D P25100 3/20 0.56
ADRA1A P35348 3/20 0.56
ADRA1B P35368 3/20 0.56
GAK O14976 2/20 0.54
RIPK2 O43353 2/20 0.54
COQ8A Q8NI60 2/20 0.54
NLK Q9UBE8 2/20 0.54
EPHB6 O15197 1/20 0.54
STK16 O75716 1/20 0.54
ABL1 P00519 1/20 0.54
ACVR1 Q04771 1/20 0.54
AAK1 Q2M2I8 1/20 0.54
NPC1 O15118 1/20 0.53
NCOA1 Q15788 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
CYP1A2 P05177 10/20 0.52
CYP3A4 P08684 10/20 0.52
CYP2C19 P33261 10/20 0.52
CYP2D6 P10635 9/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25214218 0.94 HTR1A (0.50) HTR1AADRA1DADRA1AADRA1BGAK
Formic Acid SCHEMBL30452291 0.94 HTR1A (0.50) HTR1AADRA1DADRA1AADRA1BGAK
SCHEMBL24252447 0.91 HTR1A (0.58) HTR1AADRA1DADRA1AADRA1BGAK
SCHEMBL1584878 0.83 CYP1A2 (0.73) NPC1NCOA1NCOA3CYP1A2CYP3A4
SCHEMBL27143212 0.80 CYP1A2 (0.52) NPC1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL24252882 0.79 CYP1A2 (0.55) HTR1AADRA1DADRA1AADRA1BGAK
SCHEMBL30451870 0.79 CYP1A2 (0.55) HTR1AADRA1DADRA1AADRA1BGAK
SCHEMBL30880614 0.79 GAK (0.65) HTR1AADRA1DADRA1AADRA1BGAK
SCHEMBL30380040 0.78 CYP1A2 (0.56) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL25260108 0.77 CYP1A2 (0.52) NPC1CYP1A2CYP3A4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 HTR1A 2666/4885ADRA1D 3729/4885ADRA1A 4499/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 HTR1A 2666/4885ADRA1D 3729/4885ADRA1A 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.